April 9, 2024 4:34pm

As we sink into using our portfolios as toilet paper

Who stands in-front, beside and behind investors - RMi

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading!  A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio defense.

Never leave an investor uninformed! A trusted source of factual reporting!

The present and future value of RegMed Investors (RMi) NEWS sheds light on the stem, cell and gene therapy sector’s risks to share pricing and the sector’s upside acrobatics and potential downslides.

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence! 

 

Tuesday: The Dow closed DOWN -9.13 points or -0.02%, the S&P closed UP +7.52 points or +0.14% while the Nasdaq closed UP +52.68 points or +0.32%

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes were mixed as the Dow cratered as traders brace for key U.S. inflation report.

Hedge funds are dumping stocks and stepping up bearish wagers against equities amid the recent pullback. <CNBC>

Economic Data Docket: The March consumer price index report is slated for release Wednesday at 8:30 a.m. ET. Economists surveyed by Dow Jones expect inflation to have increased 0.3% in March on a month-over-month basis.

 

Tuesday’s RegMed Investors’ (RMi) opening bell: “WHAT and WHEN are the catalysts to move share pricing.” …  https://www.regmedinvestors.com/articles/13409

 

Advance/Decline (A/D) Line:

  • Tuesday’s advance/decline line at the open was positive with 23 incliner, 11 decliners and 1 flat; ending with a positive close of 20 incliners,12 decliners and 3 flats

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q2/24: 5 negative and 2 positive closes

Q1/24:

  • March, 1 holiday, 8 positive and 12 negative closes
  • February, 1 holiday, 9 negative and 11 positive closes
  • January: 2 holiday, 12 negative and 8 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was up +1.21% and the XBI was up +1.37%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -0.21 point or -1.32% at 14.99

 

Tuesday’s Closing Down (12 of 12):

  • Adverum Biotechnologies (ADVM -$0.57),
  • Mesoblast (MESO -$0.44 after Monday’s +$0.49),
  • Generation Bio (GBIO -$0.37 after Monday’s +$0,39).
  • Solid Biosciences (SLDB -$0.35 after Monday’s -$0.26),
  • Regenxbio (RGNX -$0.18),
  • Brainstorm Cell Therapeutics (BCLI -$0.1475),
  • Alnylam Pharmaceuticals (ALNY -$0.14 after Monday’s +$2.48),
  • Graphite Bio (GRPH -$0.09 after Monday’s -$0.09),
  • Sage Therapeutics (SAGE -$ 0.08 after Monday’s +$0.18),
  • Compass Therapeutics (CMPX -$0.03),
  • Bellicum Pharmaceuticals (BLCM -$0.0054),
  • Sangamo Therapeutics (SGMO -$0.0030),

Flat (3)

  • Harvard Apparatus RT (HRGN+$0.48),
  • Precigen (PGEN)
  • uniQure NV (QURE)

Tuesday’s Closing Up (10 of 20):

  • CRISPR Therapeutics (CRSP +$1.10 after Monday’s +$1.19),
  • BioLife Solutions (BLFS +$0.85 after Monday’s +$0.18),
  • Intellia Therapeutics (NTLA +$0.78 after Monday’s +$0.52),
  • Blueprint Medicine (BPMC +$0.66 after Monday’s -$0.11),
  • Ionis Pharmaceuticals (IONS +$0.59 after Monday’s -$0.98),
  • Beam Therapeutics (BEAM +$0.51 after Monday’s +$0.61),
  • Verve Therapeutics (VERV +$0.35 after Monday’s -$0.12),
  • Ultragenyx Pharmaceuticals (RARE +$0.59),
  • Editas Medicine (EDIT +$0.29),
  • MiMedx (MDXG +$0.12 after Monday’s -$0.10),

 

Q2/24 – April

  • Tuesday closed positive with 20 incliners, 12 decliners and 3 flat

 

The BOTTOM LINE: inflation numbers facilitate share pricing declines with a lot of people selling assets to pay taxes …

On an annual basis, inflation is seen rising to 3.5% from 3.2% in February. That hinges on whether the monthly increase tapers to 0.3% from February's 0.4%. Core inflation is expected to fall to 3.7% from 3.8% annually < Econoday>

Indexes wobbled again on Tuesday after Monday also closed POSITIVE as investors kicked off a new week that will see a fresh inflation data test for rate-cut views and the start Q1 earnings season.

 

Last week, I wrote that I favor … caution over the next few weeks! Tuesday …

  • The Dow had plunged more than 300 points at one juncture, but cut that deficit in half and was down 0.4% in recent action.
  • The S&P 500 fell 0.3% as the Nasdaq did better with a loss of just -0.2%.
  • The Dow fell below its 50-day moving average while the S&P 500 and the Nasdaq hugged their 21-day moving averages.
  • small caps on the Russell 2000 fell 0.2% as it continued to battle with the 21-day moving average amid pronounced volatility in recent sessions.
  • Volume on the Nasdaq exchange was higher compared with the same time on Monday. However, breadth offered some relief as advancers led decliners on both exchanges by a small margin. <IBD>

 

“I ALSO reiterate, “Don't chase the cell and gene therapy sector, especially with the Nasdaq extended.” Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

 

The top three (3) performing in the session:

  • Tuesday: CRISPR Therapeutics (CRSP), BioLife Solutions (BLFS) and Intellia Therapeutics (NTLA)
  • Monday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM)

The worst three (3) in the session:  

  • Tuesday: Adverum Biotechnologies (ADVM), Mesoblast (MESO) and Generation Bio (GBIO)
  • Monday: Ionis Pharmaceuticals (IONS), Vericel (VCEL) and Voyager Therapeutics (VYGR)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.